granzyme

(redirected from Granzyme B)

granzyme

(grăn′zīm)
Any of a family of proteases stored in the granules of cytotoxic T lymphocytes. They are involved in cytolytic functions.
References in periodicals archive ?
TAS Taipei -- for "To Granzyme B or Not to Granzyme B: Protecting Extracellular Matrix Proteins"
Prostate cancer cells contain low levels of proteins perforin and granzyme B, which can work together to kill cells.
Nicholl said: "It is critical that both proteins, perforin and granzyme B, are present in order to kill the tumour cells, and we found that the resveratrol helped to increase their activity in prostate tumour cells.
Prostate tumour cells contain very low levels of two proteins, perforin and granzyme B, which can function together to kill cells.
Granville and his team identified a protein-degrading enzyme called Granzyme B that is abundant in aneurysms.
Example apoptosis-inducing genes include caspase 3, caspase 4, caspase 5, Granzyme B.
In their study, levels of messenger RNA (mRNA) encoding perforin and granzyme B, 2 proteins produced by cytotoxic cells, were measured in the urine of 85 renal allograft recipients with or without an episode of acute rejection.
viDA), a private biotechnology company, today announced publication of data demonstrating that Granzyme B, the primary target of viDA's drug discovery and development program, contributes to the delay of wound healing and remodeling.
In this study it was discovered that Granzyme B was elevated in non-healing wounds and contributed to the destruction of key structural proteins that are essential for proper wound closure to proceed.
This new funding will support additional preclinical research to further demonstrate the mechanism by which extracellular Granzyme B (GzmB) contributes to the pathology of a number of inflammatory and age related conditions of the skin, musculoskeletal, cardiovascular and neurological systems.
is a platform-based, biotechnology company that is developing first in class therapeutics, across a broad range of diseases, that capitalize on its recent discovery of a new mechanism of action for a well characterized protease target, Granzyme B (GzmB).
This additional funding of $750,000 from the Business Development Bank of Canada's venture capital arm (BDC Venture Capital) marks completion of key, preclinical milestones, supporting continued development of viDA's lead molecule (a granzyme B inhibitor) as a treatment for certain fibrotic, autoimmune, degenerative and age-related chronic inflammatory diseases.